This study aimed to determine the activity of colistin plus Sulbactam and colistin plus Fosfomycin against carbapenem-resistant (CRAB). Fifteen clinical isolates were obtained from patients admitted to Phyathai II International Hospital, Bangkok, Thailand, from August 2014 to April 2015. The antimicrobial susceptibilities of colistin, Sulbactam, and Fosfomycin were evaluated using the E-test or broth microdilution and the synergistic activity of the antibacterial combinations (colistin plus Sulbactam or Fosfomycin) was determined using the chequerboard method. Clonal relationships were explored using repetitive element palindromic- (REP-) PCR. The CRAB isolates were categorized by REP-PCR in 8 groups [A-H]. All CRAB isolates were universally susceptible to colistin but only 20.0% were susceptible to Sulbactam. The MIC ranges for colistin, Sulbactam, and Fosfomycin were 0.75-2 mg/L, 2-96 mg/L, and 64-256 mg/L, respectively. A chequerboard assay revealed that the rates of synergistic and additive effect rates of colistin plus Sulbactam and colistin plus Fosfomycin were 53.3% and 73.3% of isolates, respectively. No antagonistic effect in any colistin-based combination was observed. However, almost CRAB strains in clone A showed the synergy or additive effects of colistin-Sulbactam combination, whereas the other clone (B-H) mostly showed indifferent effects. In conclusion, colistin plus Sulbactam and colistin plus Fosfomycin against CRAB seem to be interesting option but the efficacy in clinical use has to be evaluated.
